by | May 24, 2024 | Publications
Cells. 2024 May 16;13(10):853. doi: 10.3390/cells13100853. ABSTRACT Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients...
by | May 24, 2024 | Publications
Cells. 2024 May 20;13(10):879. doi: 10.3390/cells13100879. ABSTRACT Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets...
by | May 24, 2024 | Publications
Diagnostics (Basel). 2024 May 16;14(10):1030. doi: 10.3390/diagnostics14101030. ABSTRACT While high-dose therapy and autologous stem cell transplant (ASCT) remain integral to the primary treatment of newly diagnosed transplant-elble multiple myeloma (MM) patients, the...
by | May 24, 2024 | Publications
Clin Transl Sci. 2024 May;17(5):e13828. doi: 10.1111/cts.13828. ABSTRACT As a treatment for relapsed or refractory multiple myeloma (MM), carfilzomib has been associated with a significant risk of cardiovascular adverse events (CVAE). The goals of our study were to...
by | May 24, 2024 | Publications
Front Pharmacol. 2024 May 9;15:1398879. doi: 10.3389/fphar.2024.1398879. eCollection 2024. NO ABSTRACT PMID:38783962 | PMC:PMC11111930 | DOI:10.3389/fphar.2024.1398879
by | May 24, 2024 | Publications
Cureus. 2024 Apr 23;16(4):e58847. doi: 10.7759/cureus.58847. eCollection 2024 Apr. ABSTRACT Extramedullary plasmacytomas without evidence of systemic illness make up less than 5% of all plasma cell neoplasms. The incidence of extramedullary plasmacytoma of the thyroid...
